Effects of two types of hormonal contraception—oral versus intravaginal—on the sexual life of women and their partners

Abstract

Introduction

Forty years after their introduction, hormonal contraceptives still represent the most effective reversible method for family planning. In recent years, to reduce side-effects associated with the contraceptive administration, the dosage of ethinylestradiol (EE) has been gradually reduced from 50 μg to 20–15 μg and new progestogens have been introduced with a reduced androgenic activity and low side-effects. The most-used hormonal contraceptives are administered by the oral route and need daily administration, 21–24 days per cycle (Borgelt-Hansen, 2001).

However, women have recently shown an increased interest towards hormonal contraception that does not require daily intake (den Tonkelaar and Oddens, 2001).

Recently, an intravaginal contraceptive device has been developed (Nuvaring; Organon, The Netherlands), which presents a ring structure, flexible and transparent, that releases 120 μg of etonogestrel and 15 μg of EE daily. The ring can be easily inserted within the 5th day of the menstrual cycle, deep into the vagina, into the posterior fornix; it remains in place for 21 days and is then removed for a 7 day ring-free period.

Clinical trials showed that Nuvaring is an effective contraceptive with a high rate of satisfaction, good cycle control and high tolerability among users (Roumen and Dieben, 1999; Dieben et al., 2002; Novak et al., 2003, 2004).

Data related to the influence of hormonal contraception on sexual life are conflicting and they mostly refer to oral contraceptives. Some studies showed that women who take oral hormonal contraceptives have a higher frequency of sexual intercourse compared to women who use other contraceptive methods, with an increased frequency and intensity of orgasms (Wynn et al., 1975; Trussell and Westoff, 1980; Oddens, 1999) while others have shown that oral contraceptives are associated with negative effects on libido and reduced women's sexual activity (Graham et al., 1995; Sanders et al., 2001; Caruso et al., 2004).

As no studies are available in the literature focusing specifically on NuvaRing influence on users' and their partners' sexual life, we decided to perform such a study comparing this intravaginal contraceptive with a combined oral contraceptive.

Materials and methods

All women who came to the Family Planning Clinic of our Department, between August 2003 and December 2003, were asked to participate in the study for the valuation of hormonal contraceptive influence on users' and their partners' sexual activity.

The participants had to be between 22 and 34 years of age, had to have reached the age of menarche between 12 and 14 years, have a body mass index (BMI) between 20 and 22 kg/m², have an active sexual life (≥4 vaginal intercourses in the last month without any specific complaint regarding it at the admission visit) with an habitual partner (>1 year), have no abnormal menstrual cycles nor abnormal dietary requirements.

Definitive exclusion criteria included confirmed pregnancy or suspicion thereof, pregnancy or breastfeeding in the previous year, evidence of acute, chronic or progressive hepatic disease, evidence of vascular or metabolic disorders, >10 cigarettes per day, history of migraine with aura, use of psychotropic drugs, use of drugs known to influence the pharmacokinetics of contraceptive steroids, use of hormonal contraceptives in the previous year, hysterectomy or oophorectomy and all other clinically relevant contraindications for the use of hormonal contraception.

Before inclusion in the protocol, all the women provided a medical and gynaecological history and underwent a gynaecological examination, Papanicolaou test, evaluation of blood pressure, calculation of the BMI and complete haematochemical tests.

During the pre-treatment phase, each woman underwent three or four ultrasonographic evaluations between days 10 and 16 of the menstrual cycle; follicles with a diameter >15 cm were monitored until breaking or until disappearance, to evaluate the presence of a normal ovulatory cycle and the absence of pelvic or adnexal pathologies.

One hundred and sixteen out of 265 women met the inclusion criteria and were enrolled. Seventy-three women wanted to start hormonal contraception. Randomization into two groups was refused by 17 women and so the remaining 56 women were randomly divided into two groups according to a computer-generated randomization list: 28 women (group A) were assigned to Nuvaring, 28 women (group B) to an oral contraceptive containing 20 μg of EE and 150 μg of desogestrel (Mercilon; NV Organon) (Figure 1). Randomization sequence was concealed both to researchers and patients until interventions had been assigned.

Twenty-eight out of 43 patients unwilling to start hormonal contraception were randomly chosen according to a computer-generated randomization list to take part in this study as control group (group C).

The effects of each contraceptive on sexuality of the study group were evaluated for a time-period of 6 months from the beginning of the study.

The study was approved by the local ethics committee, and was performed in accordance with the Declaration of Helsinki Guidelines on Human Experimentation. Informed consent was obtained from all the enrolled patients.

Group A patients were instructed about the modality of insertion of the intravaginal contraceptive ring, deep into the posterior fornix of the vagina, on the 5th day of menstrual cycle and instructed to keep it there for 21 days. The removal of the ring was followed by a ring-free period of 7 days. Group B patients were instructed to take the contraceptive pill on the first day of the menstrual cycle for 21 days, followed by a pill-free period of 7 days.

The effects of both types of hormonal contraceptives on the sexual activity of patients was assessed by the Interviewer Ratings of Sexual Function (IRSF) which evaluates some psychological and physical aspects of sexual interactions (Bancroft et al., 1982; Tyrer et al., 1983). The IRSF is a semi-structured interview involving a standard opening question for each item, followed by further probe questions as necessary to allow the interviewer to make the rating. We used a modified version of the IRSF in our study as the interviewer had to ask a standard opening question but then the patients and their partners had to rate their score for each question on a visual analogue scale (VAS) of 100 mm (range 0–100).

The IRSF was carried out on the women and their partners for groups A and B at the baseline and after cycles 3 and 6 of contraceptive intake. The same questions were asked to patients of group C and their partners at the baseline and after spontaneous cycles 3 and 6.

The calculated differences in VAS score (ΔVAS) between baseline (VAS₀), cycle 3 (VAS₃) and cycle 6 (VAS₆) were used to evaluate the effects of the contraceptive use on sexual function for each patient for each parameter (primary outcomes) investigated through the questionnaire. The calculated differences were: ΔVAS₁=VAS₃–VAS₀; ΔVAS₂=VAS₆–VAS₀; and ΔVAS₃=VAS₆–VAS₃.

In addition, weekly frequency of sexual activity (secondary outcome) of all patients was evaluated. Furthermore women of group A and their partners were asked if they could feel the intravaginal ring during sexual intercourse.

We calculated that, to observe a significant difference (P<0.05) in the variation of the parameters of sexual function with 95% statistical significance, a sample of 20 patients in each group would be needed.

The Shapiro–Wilk's test was performed to evaluate the distribution of data for all parametric variables. Age, BMI and the duration of partners' current relationships showed a normal distribution, and differences between groups at the beginning of the study for these variables were evaluated by Student's t-test for unpaired data. The data for level of education, number of children and methods of contraception previously used showed a non-normal distribution and therefore the differences between the groups for these variables were calculated by Mann–Whitney test.

The differences between the three groups in mean ΔVAS and in baseline VAS score were statistically evaluated by Mann–Whitney test for independent variables. The intra- and inter-group differences in weekly frequency of sexual intercourse were statistically evaluated by Wilcoxon test and Mann–Whitney test respectively. Statistical significance was set at P<0.05.

Results

The study group consisted of 76 women. Two patients from group A and three patients from group B discontinued the contraceptive use for spotting, headaches and fluid retention. Two patients of group C were excluded from statistical analysis as they missed a scheduled visit and one patient due to pregnancy (Figure 1).

There were no differences between the three groups at baseline in terms of age, BMI, duration of relationship with partner, level of education, number of children, previous contraceptives used and weekly frequency of sexual activity (Table I). Data regarding the 17 patients willing to start hormonal contraceptive but who refused the randomization process are given in Table II. No significant differences were detected between these women and the three studied groups in terms of baseline characteristics.

At the baseline there were no significant differences between the patients of the three groups in terms of parameters investigated by IRSF (Table III).

The modification of these parameters in patients of the three groups during the six months is reported in Table III.

Improvement of sexual function in women of groups A and B after 3 months of contraceptive intake, compared to group C, is demonstrated by the positive values in ΔVAS₁ of some parameters expressing positive sexual function (pleasure, satisfaction, complicity, sexual interest, frequency and intensity of orgasms) and by the negative values in ΔVAS₁ of some parameters expressing negative sexual function (anxiousness, pain and discomfort). In both groups A and B a significant difference was reached only for some parameters (anxiousness, sexual pleasure, frequency and intensity of orgasm, satisfaction, sexual interest, complicity). In addition a significant increase in sexual fantasy was reported in patients of group A, compared to groups B and C.

Sexual interest and complicity were significantly different between groups A and B. A significant increase in the number of sexual intercourses in group A and B was noted at cycle 3 (group A, 4.3±1.2 versus 2.8±0.9, P<0.001; group B, 4.4±1.2 versus 3.1±1.2, P<0.001) and at cycle 6 (group A, 4.4±1.0 versus 2.9±0.8, P<0.001; group B, 4.5±0.8 versus 3.1±1.2, P<0.001) in comparison with basal values and with group C at cycle 3 (group A versus group C, 4.3±1.3 versus 2.9±1.0, P<0.001; group B versus group C, 4.4±1.2 versus 2.9±1.0 P<0.001) and at cycle 6 (group A versus group C, 4.4±1.8 versus 3.0±1.0, P<0.001; group B versus group C, 4.5±0.8 versus 3.0±1.0, P<0.001). No significant differences were observed between groups A and B at cycles 3 and 6 of contraceptive intake in terms of weekly frequency of sexual intercourse.

Improvement of sexual function remained nearly constant after 6 months of contraceptive use without significant differences compared to cycle 3.

As a result of their partners being in the contraceptive groups, sexual functions of the male partners were modified as shown in Figure 2. After 3 months of contraceptive intake, a significant reduction in anxiety and an increase in pleasure and satisfaction, frequency and intensity of orgasm were reported in partners of patients in groups A and B. In the partners of patients in group A, a significant increase in sexual interest, complicity and sexual fantasy was noted compared to the partners in the other groups. Like the women in the study, the improvement of sexual function in the male partners showed a substantial consistency after 6 months of therapy compared to cycle 3 of contraceptive intake.

The number of couples in group A who reported feeling the intravaginal ring during sexual intercourse is shown in Figure 3.

Discussion

Human sexuality depends on complex interactions among cognitive processes, neurophysical and biochemical mechanisms and mood (Bancroft, 1988; Basson, 2000).

Several organs are vital to a normal sexual response: the brain, however, is the centre of the sexual universe. The five senses (smell, sight, sound, taste, touch) help to relay sexual images, fantasies and ideas to the brain. The brain accepts these signals and translates them into messages the body can understand. These messages include signals to increase blood flow and release sex hormones, such as estrogen, testosterone and vasoactive substances (Walton and Trashawn, 2003).

Estrogens increase blood flow to the brain and the vagina, increase vibratory sensation peripherally and have a positive effect on nerve growth and nerve transmission (Berman and Goldstein, 2001); levels of estradiol <50 pg/ml have been correlated with sexual complaints (Sarrel, 1990).

Testosterone seems to play a central role in controlling sex drive through receptor-mediated activities. In fact the hypothalamus, which controls sexual function and mood, contains dense estrogen and testosterone receptors (DeCherney, 2000).

On the other hand, progesterone seems to have an inhibitory effect on human sexuality: the pre-menstrual progesterone fall is associated with an increase of peri-menstrual desire, at least in women not suffering from pre-menstrual syndrome (Graziottin, 2000).

It is conceivable that hormonal contraceptives might modify the neuroendocrine pattern in women, affecting their sexuality. Available data refer to oral hormonal contraceptives but are interpreted in different ways. Indeed, some studies report a higher frequency of sexual intercourse, frequency and intensity of orgasm in women who take oral contraceptives compared to controls (Wynn et al., 1975; Trussell and Westoff, 1980) and to other contraceptive methods (Oddens, 1999). In particular, positive effect on sexual life was observed in 44% of oral contraception users compared to 11, 28 and 36% of other contraceptive method users such as condoms, natural methods and intrauterine device (Oddens, 1999).

The mechanism of the presumed positive action of hormonal contraception on sexual activity is still unclear. The psychological safety reassurance resulting from use of a very effective method of contraception reduces the fear of an unwanted pregnancy and therefore increases desire and sexual satisfaction (Masters and Johnson, 1987). It is possible to observe an increased compliance with less negative effects on the sexual life of a woman who uses an effective and safe method of contraception (Oddens, 1999). Therefore, these positive effects on sexual function could stem from the ability to separate sexual activity for procreation purposes from that of pleasure (Egarter et al., 1999).

On the contrary, other authors have demonstrated how oral contraceptives have a negative effect on the libido and sexual function in women (Graham et al., 1995; Sanders et al., 2001; Caruso et al., 2004). These effects, however, seem to be temporary (Graham et al., 1995).

The mechanism of negative influence on the sexual activity of the user are still unclear. In any case, dryness of the vagina due to the reduction of EE dosage of the new contraceptive pill, and the hypoandrogenism due to the increase of sex hormone-binding globulins, with the consequent reduction in free testosterone level, seem to be the basis for libido reduction (Coenen et al., 1996). In addition the new contraceptive pills contain a new generation of progestins which have a reduced androgenic activity compared to the antecedent.

The influence of contraception on sexual life is an important factor when deciding upon the choice of method of contraception by women (Graham et al., 1995).

A new intravaginal hormonal contraceptive ring (Nuvaring) was recently introduced; because of the position of the ring in the vagina during sexual intercourse, an influence on sexual activity of the users and their partners could be envisaged.

In our study it was possible to observe a significant reduction in anxiousness relating to sexual activity, both in the women and their partners, in both groups using contraception compared to control group. In addition, a significant increase in the frequency of sexual intercourse, pleasure and satisfaction, complicity, sexual interest and intensity of orgasm was observed in both groups using contraception compared to the control group. Improvement in sexual function in the partners of the two groups using contraception was observed. The positive effects are similar to previous studies, stressing the strong effect of psychological reassurance resulting from use of very effective contraception methods, which has notably improved the sexual function of users and partners (Masters and Johnson, 1987; Egarter et al., 1999).

We are aware that our study has several limitations. First, the major limitation of the present study is the lack of placebo-controlled groups. Enrolling a sufficient number of subjects unwilling to use hormonal contraception but keen to accept the use of a hormone-less vaginal ring would have been difficult.

Another limitation of our study is that the control group was not randomized; however, the 28 subjects of group C were chosen from a group of 43 subjects according to a computer-generated randomization list.

Finally we do not feel that the lack of blinding of both users and interviewers could have affected the results. Indeed when patients and their partners answered the questions, they answered not only with ‘yes’ or ‘no’ or with ‘a number’, but they obviously tried to explain the meaning of their answers, very often using the words ‘pill’ and ‘ring’ in their sentences. If interviewers had been blinded to group assignment, the study would have been theoretically blinded, but the interviewers would have been aware of patient group assignment in most cases.

A particularly interesting finding was the significant increase in sexual fantasies in patients treated with Nuvaring compared to patients using oral contraception. Since a small percentage of women reported feeling the intravaginal ring during intercourse, it could be speculated that the presence of a foreign body in the vagina could stimulate the woman's mind, making the sexual act more exciting. This could therefore explain the significant increase in sexual interest and complicity in patients using intravaginal contraception ring in comparison with oral contraceptive users. However, it cannot be excluded that these findings are related to the better compliance of this contraceptive method.

In a global improvement of sexual activity in partners of both contraception groups, a more significant increase in sexual interest, complicity and sexual fantasy was observed only in partners of patients using Nuvaring. The presence of the ring in the vagina would seem to be a positive stimulus to the male with positive effects on sexual interest and on the expectation concerning sexual intercourse.

A possible explanation for this finding may be that partners were aware of a ‘foreign body’ inside the partner's vagina, eliciting psychological excitation rather than the physical sensation of touching it. On the other hand, it cannot be excluded that the sensation of touching the ring may positively affect the partner's sexuality because the ring represents a reminder of the hormonal protection against unintended pregnancies.

However, due to the inability of eliciting a true measure of the presence of a placebo-effect (i.e. presence of a plastic ring in the vagina) and the impact of the different hormones and their levels in the two groups using contraception, a definitive conclusion regarding the main cause of the observed intergroup differences cannot be drawn from this study.

In conclusion, the use of both hormonal contraceptives tested seems to have a positive effect on some aspects of sexual function in the users and their partners. Moreover, the intravaginal contraceptive ring, which is as effective as other contraceptives, seems to implement a further positive effect on the psychological aspect of both women and their partners, which is evident from an improved complicity and sexual satisfaction.

Figure 1.

Open in new tabDownload slide

Flow diagram of patients enrolled in the study.

Figure 2.

Open in new tabDownload slide

Effects on partners' sexual function with an intravaginal hormonal contraceptive and a combined oral contraceptive. *P<0.001 versus group B; ^§P<0.001 versus group C. Group A: intravaginal hormonal contraceptive; group B: combined oral contraceptive; group C: controls.

Figure 3.

Open in new tabDownload slide

Percentage of women and their partners feeling the intravaginal ring during sexual intercourse.

References